title: High incidence of pruritus after large doses of hydroxyethyl starch (HES) infusions.
abstract: BACKGROUND
  There are several studies indicating a correlation between treatment with hydroxyethyl starch (HES) and pruritus. In order to see whether there is a possible dose-response relationship between HES and pruritus, we retrospectively studied 50 patients who had received HES in varying doses (cumulative dose 500-19500 ml) as hemodilution therapy after subarachnoid hemorrhage.
  
  
  METHODS
  Of 50 consecutive patients, 6 were excluded due to severe neurological sequelae. A questionnaire was sent to the remaining 44 patients at 6 months (5-12 months) median (range) after the end of HES treatment.
  
  
  RESULTS
  We received answers from 37 patients, of whom 54% reported pruritus. On average pruritus lasted for 15 weeks. There was significantly more pruritus in patients who received more than 5000 ml of HES versus those who received less than 5000 ml (P=0.023). Pruritus had a delayed onset and appeared as pruritic crises lasting for 2-30 min. It had a patchy distribution in most patients and no predilected locations. In 4 patients (20%) the pruritus lasted longer than 21 weeks.
  
  
  CONCLUSIONS
  Our study indicates that there is a dose-dependency for the incidence of HES-induced pruritus, and that in some cases the pruritus may be severe and long-lasting.
authors: Department of Anaesthesiology and Intensive Care, Faculty of Health Sciences, University Hospital, Linköping, Sweden. Peter.Kimme@lio.se
authors: P
authors: P
authors: Kimme
authors: B
authors: B
authors: Jannsen
authors: T
authors: T
authors: Ledin
authors: A
authors: A
authors: Gupta
authors: M
authors: M
authors: Vegfors
mesh_terms: D001810:Blood Volume / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage / Q000009:adverse effects*; D007262:Infusions, Intravenous; D002532:Intracranial Aneurysm / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010952:Plasma Substitutes / Q000008:administration & dosage / Q000009:adverse effects*; D011537:Pruritus / Q000139:chemically induced* / Q000473:pathology; D012189:Retrospective Studies; D013345:Subarachnoid Hemorrhage / Q000628:therapy; D020301:Vasospasm, Intracranial / Q000150:complications
chemical_list: D006895:Hydroxyethyl Starch Derivatives; D010952:Plasma Substitutes